Combining multiple peptides together represents additional risks from unknown/untested drug-drug interactions
p = 0.02) ( Based on a pooled analysis of phase III clinical trials, it was found that GLP-1 RAs may pose a slightly elevated risk of pancreatitis (38 events, 17,775 patient-years of exposure) compared to the alternative treatment (9 events, 5,863 patient-years of exposure
Table 12: Results at Week 26 in a Trial Comparing TRESIBA at Same and Alternating Times to Insulin Glargine U -100 in Adult Patients with Type 2 Diabetes Mellitus on OAD(s)* Study H TRESIBA Administered at the Same Time Each Day in Combination with a Rapid Acting Insulin Analog at Mealtimes in Adult Patients The efficacy of TRESIBA was evaluated in a 52 week randomized, open label, multicenter trial in 992 patients with type 2 diabetes mellitus inadequately controlled on premix insulin, bolus insulin alone, basal insulin alone, oral antidiabetic agents (OADs) alone or any combination thereof
4.Visible results take time - Glutathione shows brightening in 4-6 weeks, whereas Collagen improves firmness and elasticity over 8-12 weeks
Future studies are still needed evaluating the safety and efficacy of BPC 157 in humans
